Novartis

U.S. stocks finished the day near session lows as investors found little reason to be bullish. Housing data came in poor and failed to rally the bulls. Several Fed members raised the idea of a rate hike but “participants agreed that, with the unemployment rate approaching 6.5 percent, it would...

U.S. stocks rose today as investors and traders felt that there were plenty of bargains in the market to be found. "Today is just a bounce. I don't think there is really that much behind it, other than some bargain hunters stepping in," Robert Pavlik, a chief market strategist said to CNBC....

U.S. stocks continued its losses on an accelerated basis on Monday. Investors are in clear panic mode following a report that U.S manufacturing activity expanded at a slower pace in January. The Dow plunged more than 300 points while the S&P 500 and Nasdaq both fell more than two percent as...

U.S. stocks were unable to keep yesterday's momentum and ended the day sharply lower. The Dow suffered yet another triple digit decline with the S&P 500 and Nasdaq indices shedding more than one percent. In Ben Bernanke's final meeting as Fed chief, the FOMC tapered its monthly bond...

The earnings crunch is on this week. Highlights will include reports from Amazon.com, Apple, Boeing, Comcast, Facebook, Google and Yahoo! All of them are expected to report year-over-year growth in per-share earnings. But analysts are looking for declining profits from the likes of Caterpillar,...

Major indices continued to plummet on Friday with no economic data released that could rejuvenate the market. Investors remain worried about a Chinese slowdown, a mixed-bag of corporate results on Wall Street and possible further tapering just around the corner as the Fed meets again next...

While not offering any specifics, investors seemed comfortable enough with Dennis Lockhart's comments to end the week on a positive note. While speaking to CNBC the Atlanta Fed chief commented that tapering will begin “when the economy is ready and when the market is ready.” Lockhart also noted...

Among leading biotech and emerging pharmaceutical companies, short sellers moved on BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Regeneron Pharmaceuticals (NASDAQ: REGN) the most between the August 30 and September 13 settlement dates. The number of shares sold short in...

This weekend in Barron's online: managing health care expenses for the long term, as well as the prospects for GE, Nexstar Broadcasting, United Rentals, Approach Resources and more. Cover Story "How to Protect Your Health and Wealth" by Beverly Goodman. In this week's cover story in Barron's,...

Among leading biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw significant percentage declines in short interest between the July 31 and August 15 settlement dates. Short sellers also shied away...

On Sunday, after months of trying to work out a deal, Amgen (NASDAQ: AMGN) and Onyx (NASDAQ: ONXX) announced that Amgen will acquire Onyx for $125 per share valuing the deal as $10.4 billion. The announcement is about as much of a surprise as those two flirtatious coworkers that later told...

Apple (NASDAQ: AAPL), CBS (NYSE: CBS), Merck (NYSE: MRK) and Wal-Mart (NYSE: WMT) all have or are expected to have monster stock repurchase plans of more than $5 billion. Below, we take a quick look at how these stocks have fared and what analysts expect from them. When it comes to returning...

Among biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Onyx Pharmaceuticals (NASDAQ: ONXX) and Pharmacyclics (NASDAQ: PCYC) saw the most significant percentage declines in short interest between the June 28 and July 15 settlement dates. Short sellers also shied away from...

Among biotech and emerging pharmaceutical companies, Gilead Sciences (NASDAQ: GILD) and Onyx Pharmaceuticals (NASDAQ: ONXX) saw the most significant rises in short interest between the June 14 and June 28 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena...

Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new team includes recommendations to buy shares of Antares Pharma (NASDAQ: ATRS), Intercept Pharmaceuticals (NASDAQ: ICPT), Questcor Pharmaceuticals (NASDAQ: QCOR) and ViroPharma...